Joris Winderickx
Corporate Officer/Principal bij reMYND NV
Actieve functies van Joris Winderickx
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Corporate Officer/Principal | 30-05-2012 | - |
Directeur/Bestuurslid | 01-01-2002 | 30-05-2012 | |
Oprichter | 09-11-2009 | - |
Loopbaan van Joris Winderickx
Eerdere bekende functies van Joris Winderickx
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Royal Flemish Chemical Society | Oprichter | - | - |
ADx NeuroSciences NV
ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Directeur/Bestuurslid | - | - |
Katholieke Universiteit Leuven | Corporate Officer/Principal | - | - |
Opleiding van Joris Winderickx
Katholieke Universiteit Leuven | Doctorate Degree |
Statistieken
Internationaal
België | 5 |
Operationeel
Director/Board Member | 2 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Commercial Services | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Commercial Services |
Royal Flemish Chemical Society | |
ADx NeuroSciences NV
ADx NeuroSciences NV BiotechnologyHealth Technology ADx NeuroSciences NV develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The company was founded in 2011 by Paul Appermont, Koen Dewaele, Hugo Vanderstichele and Eugeen Vanmechelen and is headquartered in Ghent, Belgium. | Health Technology |
- Beurs
- Insiders
- Joris Winderickx
- Ervaring